病例报告：一名复发性晚期尤因肉瘤（EWS）患者在接受Vigil免疫治疗后出现免疫介导的完全缓解。

Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.

作者信息

Ghisoli Maurizio, Rutledge McCarley, Stephens Philip J, Mennel Robert, Barve Minal, Manley Meghan, Oliai Bahram R, Murphy Kathleen M, Manning Luisa, Gutierrez Belen, Rangadass Priyanka, Walker Ashli, Wang Zhaohui, Rao Donald, Adams Ned, Wallraven Gladice, Senzer Neil, Nemunaitis John

机构信息

*Mary Crowley Cancer Research Centers †Texas Oncology, P.A. ‡Medical City Dallas Hospital ∥ProPath ¶Gradalis Inc. #Strike Bio, Dallas, TX §Foundation Medicine, Cambridge, MA.

出版信息

J Pediatr Hematol Oncol. 2017 May;39(4):e183-e186. doi: 10.1097/MPH.0000000000000822.

DOI:10.1097/MPH.0000000000000822

PMID:28338569

Abstract

Ewing sarcoma is a highly resistant disease with a <10% chance of survival at 5 years after failure of frontline chemotherapy. This is a case report of an Ewing sarcoma patient with metastatic disease recurrence <2 years after standard chemotherapy/radiation who achieved a durable and sustained complete response after 2 series of treatments with Vigil (GMCSF/bi-shRNA furin DNA autologous tumor immunotherapy) serially manufactured from first and second recurrences with ELISPOT assay correlation. Results support justification of further testing of Vigil with ELISPOT assay as a biomarker to assess level of immune response and correlation with disease control.

摘要

尤因肉瘤是一种具有高度耐药性的疾病，一线化疗失败后5年生存率低于10%。本文报告了一例尤因肉瘤患者，该患者在标准化疗/放疗后不到2年出现转移性疾病复发，在接受了由首次和第二次复发肿瘤连续制备并经ELISPOT分析验证的Vigil（GMCSF/双短发夹RNA弗林蛋白酶DNA自体肿瘤免疫疗法）进行的2个疗程治疗后，实现了持久且持续的完全缓解。结果支持进一步用ELISPOT分析检测Vigil作为生物标志物以评估免疫反应水平及其与疾病控制相关性的合理性。